The optimal choice of induction immunosuppression for elderly kidney transplant recipients remains unclear. Although alemtuzumab has been associated with escalating risk of death and graft loss in this population, this risk has not been adequately explored. The purpose of this study was to compare the safety and efficacy of alemtuzumab with basiliximab induction in this population.
Methods:
This is a retrospective matched cohort study of kidney transplant recipients aged ≥65 years. Patients who received alemtuzumab induction were matched (1:2) to a basiliximab control. The primary outcome was allograft survival. The incidence of acute rejection, infection, and all-cause mortality was measured.
Results:
Fifty-one and 102 patients were included in the alemtuzumab and basiliximab groups, respectively. Baseline demographics were similar between groups, except for more living donor transplant recipients in the alemtuzumab group (26/51 [51%] vs 31/102 [30.4%], P = .02). Acute cellular rejection occurred more frequently within the first year in the basiliximab group (P = .02). There was no difference in rates of infection within the first year. Graft and patient survival rates were similar over the follow-up period. Patients receiving basiliximab had a higher glomerular filtration rate at 2 years posttransplant (59 mL/min/1.73 m2 vs 49 mL/min/1.73 m2, P = .03).
Conclusions:
Alemtuzumab induction is associated with similar outcomes to basiliximab in elderly kidney transplant recipients.
HartASmithJMSkeansMA, et al.OPTN/SRTR annual data report 2014: kidney. Am J Transplant. 2016;16(suppl 2):11–16.
2.
BradleyBA. Rejection and recipient age. Transpl Immunol. 2002;10(2-3):125–132.
3.
WeiskopfDWeinbergerBGrubeck-LoebensteinB. The aging of the immune system. Transpl Int. 2009;22(11):1041–1050.
4.
GillJSampaioMGillJS, et al.Induction immunosuppressive therapy in the elderly kidney transplant recipient in the United States. Clin J Am Soc Nephrol. 2011;6(5):1168–1178.
5.
Meier-KriescheHUOjoAOHansonJ, et al.Increased immunosuppressive vulnerability in elderly renal transplant recipients. Transplantation. 2000;5(5):885–889.
6.
Meier-KriescheHUOjoAOHansonJA, et al.Exponentially increased risk of infectious death in older renal transplant recipients. Kidney Int. 2001;4(4):1439–1543.
7.
MartinsPNPratschkeJPrascherA, et al.Age and immune response in organ transplantation. Transplantation. 2005;79(2):127–132.
8.
BadowskiMGurk-TurnerCCangroC, et al.The impact of reduced immunosuppression on graft outcomes in elderly renal transplant recipients. Clin Transplant. 2009;23(6):930–937.
9.
GabardiSMartinSTRobertsKL, et al.Induction immunosuppressive therapies in renal transplantation. Am J Health-Syst Pharm. 2011;68(3):211–218.
10.
HardingerKLBrennanDCKleinCL. Selection of induction therapy in kidney transplantation. Transpl Int. 2013;26(7):662–672.
BrennanDCDallerJALakeKD; et al.Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med. 2006; 355(19):1967–1977.
13.
IssaNCFishmanJA. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis. 2009;48(6):772–786.
14.
AlangadenGJThyagarajanRGruberSA, et al.Infectious complications after kidney transplantation: current epidemiology and associated risk factors. Clin Transplant. 2006;20(4):401–409.
15.
LebranchyYBridouxFBuchlerM, et al.Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant recipients receiving MMF-containing triple therapy. Am J Transplant. 2002;2(1):48–56.
16.
MouradGGarrigueVSquiffletJP, et al.Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. Transplantation. 2001;72(6):1050–1055.
17.
BustamiRTOjoAOWolfeRA, et al.Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant. 2004;4(1):87–93.
MorganRDO’CallaghanJMKnightSR, et al.Alemtuzumab induction therapy in kidney transplantation: a systemic review and meta-analysis. Transplantation. 2012;93(12):1179–1188.
20.
HanawayMJWoodleESMulgaonkarS, et al.Alemtuzumab induction in renal transplantation. N Engl J Med. 2011; 364:1909–1919.
21.
CalneRMoffattSDFriendPJ, et al.Campath 1H allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation. 1999; 68(10):1613–1616.
22.
MorrisPJRussellNK. Alemtuzumab (Campath-1H): a systematic review in organ transplantation. Transplantation. 2006; 81(10):1361–1367.
23.
KirkADHaleDAMannonRB, et al.Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation. 2003;76(1):120–129.
24.
KnechtleSJPirschJDFechnerHJJr, et al.Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant. 2003;3(6):722–730.
25.
WatsonCJBradleyJAFriendPJ, et al.Alemtuzumab (CAMPATH 1H) induction in cadaveric kidney transplantation—efficacy and safety at five years. Am J Transplant. 2005;5(6):1347–1353.
26.
HuangEChoYWHayashiR, et al.Alemtuzumab induction in deceased donor kidney transplantation. Transplantation. 2007;84(7):821–828.
27.
SampaioMSKadiyalaAGillJ, et al.Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation. Transplantation. 2009;88(7):904–910.
28.
HurstFPAltieriANeeR, et al.Poor outcomes in elderly kidney transplant recipients receiving alemtuzumab induction. Am J Nephrol. 2011;34(6):534–541.
LeveyASBoschJPLewisJB; et al.Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130(6):461–470.
31.
SolezKColvinRBRacusenLC, et al.Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8(4):753–760.
32.
HaasMSisBRacusenLC, et al.Banff 2013 meeting report: inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14(2):272–283.
33.
DubberkeERBurdetteSD; The AST Infectious Diseases Community of Practice. Clostridium difficile infections in solid organ transplantation. Am J Transplant. 2013;13(suppl 4):42–49.
34.
HirschHHRandhawaP; The AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation. Am J Transplant. 2013;13(suppl 4):179–188.
HalloranPF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351(26):2715–2729.
37.
PascaulJPirschJTorrealbaJ, et al.Antibody-mediated rejection (AMR) in renal allograft recipients treated with alemtuzumab induction. Am J Transplant. 2008;8(suppl 2):237. Abstract.
KaufmanDBLeventhalJRAxelrodD, et al.Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction—long term results. Am J Transplant. 2005;5(10):2539–2548.
40.
CiancioGBurkeGWGaynorJJ, et al.A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immunosuppressive monitoring. Transplantation. 2005;80(4):457–465.
41.
CiancioGBurkeGWGaynorJJ, et al.A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Clin Transplant. 2008;22(2):200–210.
42.
3C Study Collaborative Group, HaynesTHardenPJudgeP, et al.Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C study): a randomized trial. Lancet. 2014;384(9955):1684–1690.
43.
MartinSIMartyFMFiumaraK, et al.Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis. 2006;43(1):16–24.
44.
CaiJTerasakiPIBloodDD, et al.Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1 H induction. Transplantation. 2004;78(6):919–924.
45.
GrailerANicholsJHullettD, et al.Inhibition of human B cell responses in vitro by RS-61443, cyclosporine A and DAB486 IL-2. Transplant Proc. 1991;23(1 pt 1):314–315.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
